Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 88

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 88
---
 Accrued manufacturing expenses7,953 11,652 Accrued R&D expenses3,293 5,898 Operating lease liabilities, current portion (1)7,391 6,889 Accrued royalties (2)5,127 8,105 Other accrued expenses9,337 6,989 Total$77,739 $76,352 _______________________________(1)  Refer to Note 12, Leases.(2)  Refer to Note 15, Commitments and Contingencies.

20

Accrued Product Returns and RebatesJune 30,2025December 31,2024(unaudited)Accrued product rebates$134,892 $115,330 Accrued product returns46,024 53,375 Total$180,916 $168,705 

15.    Commitments and Contingencies

Product LicensesThe Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement.Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, ONAPGO, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense incurred for these acquired products is recognized as Cost of goods sold in the condensed consolidated statements of earnings. Navitor Development AgreementIn April 2020, the Company entered into a development agreement (Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor Inc.). The Company can terminate the Development Agreement upon 30 days' notice. Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) for treatment-resistant depression. The Company agreed to bear certain Phase I and Phase II development costs incurred by either party, up to a maximum of $50 million, which amount could be increased under the terms of the Development Agreement upon Navitor's request and the Company's consent. In 2020, the Company paid a